CHI3L1 and COVID-19: First, the unsatisfactory sample size, due to COVID-19-dependent difficulties in obtaining blood samples within the planned timeframe, means that further studies with a large sample are needed to evaluate the utility of GAAG, COMP, and YKL-40 as biomarkers of disease progression and to assess the effectiveness of treatment.